MannKind To Pay $23M In Investor Suit Over Diabetes Drug

Law360, Los Angeles (September 10, 2012, 5:09 PM EDT) -- A California judge on Monday preliminarily approved MannKind Corp.'s $23 million securities class action settlement with shareholders who claim the pharmaceutical company misled them about the regulatory approval prospects of its diabetes drug Afrezza, allegedly causing up to $158 million in investor losses.

U.S. District Judge Gary A. Feess granted preliminary approval to MannKind’s settlement with investors who purchased its stock between May 4, 2010, and Feb. 11, 2011, and also signed off on a deal imposing corporate governance reforms in a related derivative shareholder lawsuit...
To view the full article, register now.

Related

Sections

Case Information

Case Title

Justin Mui v. Mannkind Corporation et al - THE MANNKIND SECURITIES ACTIONS


Case Number

2:11-cv-00929

Court

California Central

Nature of Suit

Securities/Commodities

Judge

Gary A. Feess

Date Filed

January 31, 2011


Case Title

Donald Talley v. Alfred E Mann et al


Case Number

2:11-cv-05003

Court

California Central

Nature of Suit

Stockholders Suits

Judge

Gary A. Feess

Date Filed

June 12, 2011

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.